Zhao-Lun Li1, Xuan Liang2, He-Cheng Li1, Zi-Ming Wang1, Tie Chong1. 1. Department of Urology, the Second Affiliated Hospital, Xi-an Jiaotong University Medical College, Xi-an 710004, China. 2. Department of Oncology, the First Affiliated Hospital, Xi-an Jiaotong University Medical College, Xi-an 710061, China.
Abstract
AIM: Adenovirus-mediated gene therapy is a novel therapeutic approach for the treatment of cancer, in which replication of the virus itself is the anticancer method. However, the success of this novel therapy is limited due to inefficient delivery of the virus to the target sites. In this study, we used dendritic cells (DCs) as carriers for conditionally replicating adenoviruses (CRAds) in targeting prostate carcinoma (PCa). METHODS: Four types of CRAds, including Ad-PC (without PCa-specific promoter and a recombinant human tumor necrosis factor, rmhTNF, sequence), Ad-PC-rmhTNF (without PCa-specific promoter), Ad-PPC-NCS (without an rmhTNF sequence) and Ad-PPC-rmhTNF, were constructed. The androgen-insensitive mouse PCa RM-1 cells were co-cultured with CRAd-loading DCs, and the viability of RM-1 cells was examined using MTT assay. The in vivo effects of CRAd-loading DCs on PCa were evaluated in RM-1 xenograft mouse model. RESULTS: Two PCa-specific CRAds (Ad-PPC-NCS, Ad-PPC-rmhTNF) exhibited more potent suppression on the viability of RM-1 cells in vitro than the PCa-non-specific CRAds (Ad-PC, Ad-PC-rmhTNF). In PCa-bearing mice, intravenous injection of the PCa-specific CRAd-loading DCs significantly inhibited the growth of xenografted tumors, extended the survival time, and induced T-cell activation. Additionally, the rmhTNF-containing CRAds exhibited greater tumor killing ability than CRAds without rmhTNF. CONCLUSION: DCs may be an effective vector for the delivery of CRAds in the treatment of PCa.
AIM: Adenovirus-mediated gene therapy is a novel therapeutic approach for the treatment of cancer, in which replication of the virus itself is the anticancer method. However, the success of this novel therapy is limited due to inefficient delivery of the virus to the target sites. In this study, we used dendritic cells (DCs) as carriers for conditionally replicating adenoviruses (CRAds) in targeting prostate carcinoma (PCa). METHODS: Four types of CRAds, including Ad-PC (without PCa-specific promoter and a recombinant humantumornecrosis factor, rmhTNF, sequence), Ad-PC-rmhTNF (without PCa-specific promoter), Ad-PPC-NCS (without an rmhTNF sequence) and Ad-PPC-rmhTNF, were constructed. The androgen-insensitive mouse PCa RM-1 cells were co-cultured with CRAd-loading DCs, and the viability of RM-1 cells was examined using MTT assay. The in vivo effects of CRAd-loading DCs on PCa were evaluated in RM-1 xenograft mouse model. RESULTS: Two PCa-specific CRAds (Ad-PPC-NCS, Ad-PPC-rmhTNF) exhibited more potent suppression on the viability of RM-1 cells in vitro than the PCa-non-specific CRAds (Ad-PC, Ad-PC-rmhTNF). In PCa-bearing mice, intravenous injection of the PCa-specific CRAd-loading DCs significantly inhibited the growth of xenografted tumors, extended the survival time, and induced T-cell activation. Additionally, the rmhTNF-containing CRAds exhibited greater tumor killing ability than CRAds without rmhTNF. CONCLUSION: DCs may be an effective vector for the delivery of CRAds in the treatment of PCa.
Authors: Hulin Wu; Arun Kumar; Hongyu Miao; Jeanne Holden-Wiltse; Timothy R Mosmann; Alexandra M Livingstone; Gabrielle T Belz; Alan S Perelson; Martin S Zand; David J Topham Journal: J Immunol Date: 2011-09-23 Impact factor: 5.422
Authors: Tineke Wolters; Monique J Roobol; Pim J van Leeuwen; Roderick C N van den Bergh; Robert F Hoedemaeker; Geert J L H van Leenders; Fritz H Schröder; Theodorus H van der Kwast Journal: Eur Urol Date: 2009-07-29 Impact factor: 20.096
Authors: Sari Pesonen; Iulia Diaconu; Lotta Kangasniemi; Tuuli Ranki; Anna Kanerva; Saila K Pesonen; Ulrike Gerdemann; Ann M Leen; Kalevi Kairemo; Minna Oksanen; Elina Haavisto; Sirkka-Liisa Holm; Aila Karioja-Kallio; Satu Kauppinen; Kaarina P L Partanen; Leena Laasonen; Tima Joensuu; Tuomo Alanko; Vincenzo Cerullo; Akseli Hemminki Journal: Cancer Res Date: 2012-02-09 Impact factor: 12.701
Authors: E J Ilett; R J Prestwich; T Kottke; F Errington; J M Thompson; K J Harrington; H S Pandha; M Coffey; P J Selby; R G Vile; A A Melcher Journal: Gene Ther Date: 2009-03-12 Impact factor: 5.250
Authors: Briana Jill Williams; Shilpa Bhatia; Lisa K Adams; Susan Boling; Jennifer L Carroll; Xiao-Lin Li; Donna L Rogers; Nikolay Korokhov; Imre Kovesdi; Alexander V Pereboev; David T Curiel; J Michael Mathis Journal: PLoS One Date: 2012-10-08 Impact factor: 3.240
Authors: A M Moodycliffe; V Shreedhar; S E Ullrich; J Walterscheid; C Bucana; M L Kripke; L Flores-Romo Journal: J Exp Med Date: 2000-06-05 Impact factor: 14.307